Samyang Biopharmaceuticals Corporation

Pharma

Seoul, South Korea, South Korea · Est. 1979

Samyang Biopharmaceuticals is a South Korean biopharmaceutical company focused on developing and commercializing innovative therapies for gastrointestinal and oncology diseases.

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

Clinical Trials↗

All sponsored trials (all statuses)

Activity

Key Events

Mar 31, 2022TrialCompare the Efficacy and the Safety of Taxotere and Nanoxel M as Neoadjuvant Chemotherapy in Breast Cancer

Oct 28, 2018TrialStudy to Compare Pharmacokinetic Property of SYO-1644 Tab. and Nexavar Tab. in Healthy Male Volunteers

Jan 1, 2017TrialStudy to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Aug 17, 2016TrialCrossover Study to Compare Pharmacokinetic Property of SYP-1512 Tab and Revlimid Cap in Healthy Male Volunteers

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Founded1979

HQSeoul, South Korea, South Korea

Therapeutic Focus

Gastroenterologyoncologyimmunology

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)